Mario Scartozzi
About
In The Last Decade
Mario Scartozzi
321 papers receiving 6.3k citations
Peers
Comparison fields: 5 of 133
- Oncology 3.7k
- Pulmonary and Respiratory Medicine 2.1k
- Molecular Biology 1.7k
- Cancer Research 1.5k
- Pathology and Forensic Medicine 1000
Countries citing papers authored by Mario Scartozzi
This map shows the geographic impact of Mario Scartozzi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Scartozzi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Scartozzi more than expected).
Fields of papers citing papers by Mario Scartozzi
This network shows the impact of papers produced by Mario Scartozzi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Scartozzi. The network helps show where Mario Scartozzi may publish in the future.
Co-authorship network of co-authors of Mario Scartozzi
This figure shows the co-authorship network connecting the top 25 collaborators of Mario Scartozzi. A scholar is included among the top collaborators of Mario Scartozzi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Scartozzi. Mario Scartozzi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 2 | |
| 2 | 0 | |
| 3 | 2 | |
| 4 | 1 | |
| 5 | 4 | |
| 6 | 16 | |
| 7 | 1 | |
| 8 | 11 | |
| 9 | 1 | |
| 10 | 27 | |
| 11 | 5 | |
| 12 | 6 | |
| 13 | 9 | |
| 14 | 25 | |
| 15 | 17 | |
| 16 | Profile of lenvatinib in the treatment of hepatocellular carcinoma: design, development, potential place in therapy and network meta-analysis of hepatitis B and hepatitis C in all Phase III trials | 1 |
| 17 | 7 | |
| 18 | 11 | |
| 19 | 26 | |
| 20 | 2 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.